Gilead Sciences (NASDAQ:GILD) Ticks Higher After Settling Patent Challenges
September 12 2022 - 10:28AM
TipRanks
Gilead Sciences (NASDAQ:GILD) shares are ticking upwards after the
healthcare major disclosed it has resolved litigation and patent
challenges with major generic manufacturers including Lupin,
Apotex, Macleods Pharma, Cipla, and Hetero Labs. The challenges
were related to Gilead’s Descovy, Vemlidy, and Odefsey. Under the
agreements, Gilead has granted a non-exclusive license in the U.S.
to the generic manufacturers for patents related to tenofovir
alafenamide (Descovy and Vemlidy) starting October 31, 2031, and
for Odefsey starting January 31, 2032. The development implies that
generic developers will be able to bring versions of these drugs on
the market only after 2031 and 2032.
https://www.tipranks.com/news/gilead-sciences-nasdaqgild-ticks-higher-after-settling-patent-challenges?utm_source=advfn.com&utm_medium=referral
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jan 2023 to Feb 2023
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Feb 2022 to Feb 2023